In November’s issue of Pharma Times Magazine, Mark Marfé explores the current applications of Distributed Ledger Technologies (DLT), such as blockchain, and how DLT can be used and developed to benefit companies in the pharma industry. This article looks at DLT’s role in overcoming particular challenges facing the pharma supply chain, including anti-counterfeiting, product recall, information sharing, access to financing as well as the development of smart contracts. Read
“The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age“ The pharmaceutical industry is becoming increasingly interested in digital health and serious money is being invested in the technology. Pharmaceutical companies are used to an established commercial formula for bringing new products to market, with product
The tragic death of a 21-year old student who used a search engine to look for last-resort medical treatment for his terminal cancer has recently caused public outrage and an institutional crackdown in China. According to various news reports, a student named Wei died after receiving an expensive experimental treatment, provided by a hospital he
There have been a number of recent decisions concerning Community trade marks in the Pharmaceutical sector in Europe recently, which could impact on the protection pharmaceuticals companies have when registering or defending Community trade marks. In this post we outline our Top 5 decisions.
Once more the General Court has confirmed that the relevant public in the field of pharmaceutical products – consisting both of medical professionals and patients – displays, in general, a “relatively high” level of attentiveness vis-à-vis pharmaceutical trademarks (judgment of 24 September 2014, Case T-493/12, Sanofi SA v. OHIM / GP Pharm SA). The General